Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. - sprookjes - yvandenbroek - TriplyDB

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q27852997

about

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia CIViC database The molecular mechanics of mixed lineage leukemia.Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.Ikaros and leukaemia.A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.Predictive value of (18)F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial.Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?Emerging biological therapies to treat acute lymphoblastic leukemia.Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.Treatment of Young Adults with Acute Lymphoblastic Leukemia.Continuing challenges and current issues in acute lymphoblastic leukemia.Advances in adult acute lymphoblastic leukemia therapy.Blood transfusion in hematologic intensive care unit.Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.NHE1 has a notable role in metastasis and drug resistance of T-cell acute lymphoblastic leukemia.Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.Personalized medicine in adult acute lymphoblastic leukemia.Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.

P2860

bc9a52e5b5853fd1e1bb6e7a7e4e6592b3c244d3

P248

Q26749177-1F839C9B-2F51-4091-AB33-E6CAF81EB359 Q26828511-624C033C-8458-4979-AFFB-A557E61525F0 Q27006773-AE81CFE4-AF69-4B4E-AE98-B3AD3B86E2C7 Q27612411-4EB827F0-BCB8-452B-9B55-FA7996E265FF Q34516051-3898BF46-800C-483E-B4AF-A71A5D35076F Q35100974-F429BC1A-9A56-49C3-A699-D48CA5672C80 Q35604619-A20DCEE1-A20A-470E-BAAB-1B96589671CD Q35986474-B4350B88-6A3C-4FBE-B85C-5A1374AE7DD2 Q36151241-2BB890A0-5D9C-414A-A243-1C61E5EB5E5E Q36182008-3691D5AE-49BA-4761-A7B3-BBDBE2D770FC Q36426910-5FAD8E56-387C-4A29-B776-3475581AB35C Q36781942-155C0BB9-56CE-49E9-B28E-D9A1EAEDED5E Q37140482-FFBFFD91-F5AA-4129-AA85-6A2A642F3975 Q37140487-9858A797-F8AE-487D-B3E8-790D373AD4CF Q37575938-E8DC79CD-5538-4E1D-9709-A94EDC0E4D77 Q37619915-833D72BA-7C71-4D96-99DD-467601A94E84 Q38224988-86F0D6CE-6129-43F8-BB60-AD9CB35EBB68 Q38371003-0069471F-3FEC-4F21-90D8-97CE28119F61 Q38409519-156298B0-9EE3-4EAB-B2EA-05878448E614 Q38452047-90A77233-B847-405E-9FC4-B09261E4A983 Q38667096-DFC6A91C-CB0E-49DE-92AC-7BA07C9F4758 Q38753649-1D65FBB3-EC86-4A64-9779-674EAEA87E04 Q38756821-44452E09-6720-47D0-8CC2-3E708AF3A3F1 Q38792016-53A3A488-EBBB-4748-9017-B9BA86F4B217 Q38843692-2C009C69-D54E-46C1-A8C1-6FFF6B97AB6A Q38953608-F35BA811-4A44-4373-816E-DDEDF4835A2A Q39002036-4B4C58F7-B4AA-4C17-A7EB-2C863B4C3495 Q39014321-8BDC84B0-8CC1-46FA-8280-5E89F98BAA6F Q39206217-DDDD8AE4-B99A-430C-A642-0B4C2B9E9656 Q39366299-DE853C74-0227-41BB-AF84-AA471D79184E Q39459190-92BB34B2-E2DD-4AA0-9892-77BB6CD0F5BA Q40468838-E84DDCFE-89C0-4BAA-8D6D-180E762F5993 Q41009415-39C7776E-79EB-4C33-A4AC-029DA37B8AC0 Q41389031-D64F9F13-3197-4662-AA1A-4C0CF8F0A2EE Q41724569-43491E07-0BB3-440C-804C-9779F5C5458C Q42368324-F5E09AE6-7448-49C2-9E0A-11797F779E30 Q42384621-F09F342D-9418-4B5A-8DF5-83FB3AB5109F Q42660706-9CCD01D6-5180-4959-AD28-DEEF5C94C578 Q44783681-DBB9C61B-1372-4394-BDF8-355CDC76C3F3 Q46477192-9285C31F-CD16-4E5C-BD02-B2FC8603F4B9

P2860

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q27852997

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@ast

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@en

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@nl

type

label

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@ast

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@en

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@nl

prefLabel

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@ast

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@en

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@nl

P1433

Q27852997-2386BF80-E774-4C28-B118-ADE0180B5BD1

P1476

Q27852997-B96D0E50-B0DE-4B79-A074-FF35222838A7

P2093

Q27852997-1BD2A9B1-CCEF-49FB-823D-367382318020

Q27852997-22B437CF-BBF5-4A30-8B86-EB4BF69D2FCB

Q27852997-5A8431B0-2867-4759-872C-BF33553D86BD

Q27852997-637B0F38-B6E8-4FF9-97F7-C5FC89F8B3B0

Q27852997-63A9D5D2-7451-4423-8B50-C57289A404BB

Q27852997-775E39B3-DB7A-4683-9475-CFE8152E24A9

Q27852997-7DB0B531-E7CB-4903-AD99-CDAA0026E813

Q27852997-7EB8E32D-F4E8-4EFF-9ACF-C00A2BD93802

Q27852997-87766E8A-54BC-490D-8B3D-B0B2D7BEF48E

Q27852997-8B9551D0-04AA-47A6-86E4-FB2177514CEE

P304

Q27852997-A4ECEA2F-396E-48B4-89B6-D24EB91E3D4D

P31

Q27852997-715245D9-508D-4450-B8D3-5C7A9E22C92E

P3181

Q27852997-BCF3D5FE-68FF-4FE4-B91A-03EE1805DE8A

P356

Q27852997-08C33F59-2832-42EC-82FE-8A55222B4E88

P407

Q27852997-009DCDEF-3278-461B-B48C-0C0C09505D0A

P433

Q27852997-344661F1-102A-41AB-9835-E719474B4852

P478

Q27852997-99A1580D-3ED5-407E-BEB2-2BCCF12F0AD0

P50

Q27852997-1BCC26C7-A9AB-49E8-91DD-1697F068238E

Q27852997-200C4CEA-D31A-4AF4-8D9E-EC7DF14C53E6

Q27852997-4588886D-AA05-4D16-B249-DCA6B47ACD4D

Q27852997-6B1B91D4-50F3-410A-A5D9-631717E12E65

Q27852997-6F25446E-459D-41E1-B801-6F2FDCEC6F4D

Q27852997-6F3625FC-A225-46E1-BF46-85BA77EFAB52

Q27852997-ABBACD3F-3219-4319-945A-E421E8B3D795

Q27852997-DE306967-0FD8-4185-9C50-F8E949775817

Q27852997-E6B3E397-2E0D-4A8B-B04F-8CBE1542FE5E

P577

Q27852997-0BC0056F-188C-490D-A8B1-CB6E9D1F61B7

P5875

Q27852997-00A4BF31-0F7B-4C50-8E36-67168211AD8A

P698

Q27852997-F55F7DEA-518E-47DA-B464-2C6F8DA1EAD6

P921

Q27852997-A035C20C-3C49-423D-808C-E5A50669533A

P3181

P356

BLOOD-2014-01-547695

P1433

P1476

Oncogenetics and minimal resid ...... acute lymphoblastic leukemia.

@en

P2093

Beat Schaefer

http://www.w3.org/2001/XMLSchema#string

Elizabeth Macintyre

http://www.w3.org/2001/XMLSchema#string

Françoise Huguet

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Cayuela

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Vernant

http://www.w3.org/2001/XMLSchema#string

Kheira Beldjord

http://www.w3.org/2001/XMLSchema#string

Marie C Béné

http://www.w3.org/2001/XMLSchema#string

Marie-Laure Boulland

http://www.w3.org/2001/XMLSchema#string

Marina Lafage

http://www.w3.org/2001/XMLSchema#string

Nicolas Boissel

http://www.w3.org/2001/XMLSchema#string

P304

3739-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2387665

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2014-01-547695

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Nathalie Grardel

P577

2014-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261751980

http://www.w3.org/2001/XMLSchema#string

P698

24740809

http://www.w3.org/2001/XMLSchema#string

P921